Terms: = Ovarian epithelial cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Diagnosis
148 results:
1. Integrated genomic/epigenomic analysis stratifies subtypes of clear cell ovarian carcinoma, highlighting their cellular origin.
Nishijima A; Oda K; Hasegawa K; Koso T; Asada K; Ikeda Y; Taguchi A; Maeda D; Nagae G; Tsuji S; Tatsuno K; Uehara Y; Kurosaki A; Sato S; Tanikawa M; Sone K; Mori M; Ikemura M; Fujiwara K; Ushiku T; Osuga Y; Aburatani H
Sci Rep; 2024 Aug; 14(1):18797. PubMed ID: 39138354
[TBL] [Abstract] [Full Text] [Related]
2. Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.
Pierre ME; Manneh R; Hernández A; Rodríguez J; Fletcher AV; Ramírez HM; Niño OM; Gómez DA; Sanabria D; Contreras F; Pieschacón JR; Calderón PH
Rev Colomb Obstet Ginecol; 2024 Jun; 75(1):. PubMed ID: 39013199
[TBL] [Abstract] [Full Text] [Related]
3. Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.
Graybill WS; Pardo Búrdalo B; O'Malley DM; Vergote I; Monk BJ; Auranen A; Copeland LJ; Sabbatini R; Herzog TJ; Follana P; Pothuri B; Braicu EI; McCormick C; Yubero A; Moore RG; Vuylsteke P; Raaschou-Jensen N; York W; Hartman J; González-Martín A
Int J Gynecol Cancer; 2024 Jul; 34(7):1041-1050. PubMed ID: 38950925
[TBL] [Abstract] [Full Text] [Related]
4. epithelial ovarian cancer and brain metastases: might the
Sassu CM; Marchetti C; Russo G; Minucci A; Boccia SM; Benato A; Nero C; Piermattei A; Mattogno PP; Giannarelli D; Ferrandina G; Olivi A; Fagotti A; Scambia G
Int J Gynecol Cancer; 2024 Jan; 34(1):88-98. PubMed ID: 38805344
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic value of brca1 promoter methylation for patients with epithelial ovarian cancer.
Azaïs H; Garinet S; Benoit L; de Jesus J; Zizi M; Landman S; Bats AS; Taly V; Laurent-Puig P; Blons H
J Gynecol Obstet Hum Reprod; 2024 Sep; 53(7):102796. PubMed ID: 38729429
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic factors and the role of primary debulking in operable stage IVB ovarian cancer with supraclavicular lymph node metastasis: a retrospective study in Chinese patients.
Quan C; Chen X; Wen H; Wu X; Li J
BMC Cancer; 2024 May; 24(1):565. PubMed ID: 38711015
[TBL] [Abstract] [Full Text] [Related]
7. Aneuploidy Landscape in Precursors of ovarian cancer.
Wang Y; Douville C; Chien YW; Wang BG; Chen CL; Pinto A; Smith SA; Drapkin R; Chui MH; Numan T; Vang R; Papadopoulos N; Wang TL; Shih IM
Clin Cancer Res; 2024 Feb; 30(3):600-615. PubMed ID: 38048050
[TBL] [Abstract] [Full Text] [Related]
8. Germline Mutations in 12 Genes and Risk of ovarian cancer in Three Population-Based Cohorts.
Kotsopoulos J; Hathaway CA; Narod SA; Teras LR; Patel AV; Hu C; Yadav S; Couch FJ; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2023 Oct; 32(10):1402-1410. PubMed ID: 37493628
[TBL] [Abstract] [Full Text] [Related]
9. Exploring the role of a multidisciplinary hereditary gynecologic oncology clinic in epithelial ovarian cancer risk-reducing surgical decision-making practices: A mixed-methods study.
Casalino S; Bruce S; Serfas K; Altman AD; Kean S; Lambert P; McManus KJ; Hartley JN; Nachtigal MW
J Genet Couns; 2023 Jun; 32(3):728-743. PubMed ID: 36808790
[TBL] [Abstract] [Full Text] [Related]
10. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review.
Terp SK; Stoico MP; Dybkær K; Pedersen IS
Clin Epigenetics; 2023 Feb; 15(1):24. PubMed ID: 36788585
[TBL] [Abstract] [Full Text] [Related]
11. Metastatic colorectal cancer as the primary phenotype in a hereditary breast and ovarian cancer patient with Germline brca1 mutation: a case report.
Liu Y; Zhu J; Wei X; Yang D; Li S; Qian X; Li L
J Ovarian Res; 2022 Dec; 15(1):127. PubMed ID: 36463302
[TBL] [Abstract] [Full Text] [Related]
12. Evaluation of promoter hypermethylation of tumor suppressor gene brca1 in epithelial ovarian cancer.
Das J; Chandra L; Gandhi G; Amle DB; Patnayak RL; Khurana N; Saxena A
J Cancer Res Ther; 2022; 18(6):1578-1582. PubMed ID: 36412414
[TBL] [Abstract] [Full Text] [Related]
13. Systematic mapping review of guidelines for
Hughes BN; Jorgensen KA; Cummings S; Morah D; Krause K; Rauh-Hain JA; Herzog TJ
Int J Gynecol Cancer; 2023 Feb; 33(2):250-256. PubMed ID: 36368709
[TBL] [Abstract] [Full Text] [Related]
14. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and ovarian cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
[TBL] [Abstract] [Full Text] [Related]
15. Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Marmouset V; Decroocq J; Garciaz S; Etienne G; Belhabri A; Bertoli S; Gastaud L; Simand C; Chantepie S; Uzunov M; Genthon A; Berthon C; Chiche E; Dumas PY; Vargaftig J; Salmeron G; Lemasle E; Tavernier E; Delage J; Loirat M; Morineau N; Blanc-Durand F; Pautier P; Vergé V; Auger N; Thomas M; Stefani L; Lepelley M; Boyer T; Thepot S; Gourin MP; Bourquard P; Duchmann M; Morice PM; Michallet M; Adès L; Fenaux P; Récher C; Dombret H; Pagès A; Marzac C; Leary A; Micol JB;
Clin Cancer Res; 2022 Dec; 28(23):5211-5220. PubMed ID: 36201165
[TBL] [Abstract] [Full Text] [Related]
16. High detection rate from genetic testing in BRCA-negative women with familial epithelial ovarian cancer.
Flaum N; Crosbie EJ; Edmondson R; Woodward ER; Lalloo F; Smith MJ; Schlecht H; Evans DG
Genet Med; 2022 Dec; 24(12):2578-2586. PubMed ID: 36169650
[TBL] [Abstract] [Full Text] [Related]
17. Progression-free survival and overall survival after brca1/2-associated epithelial ovarian cancer: A matched cohort study.
Heemskerk-Gerritsen BAM; Hollestelle A; van Asperen CJ; van den Beek I; van Driel WJ; van Engelen K; Gómez Garcia EB; de Hullu JA; Koudijs MJ; Mourits MJE; Hooning MJ; Boere IA
PLoS One; 2022; 17(9):e0275015. PubMed ID: 36137114
[TBL] [Abstract] [Full Text] [Related]
18. CT imaging phenotypes linked to CA125 and HE4 biomarkers are highly predictive in discriminating between hereditary and sporadic ovarian cancer patients.
Manganaro L; Celli V; Viggiani V; Berardelli E; Granato T; Tartaglione S; Farina A; Catalano C; Angeloni A; Anastasi E
Tumour Biol; 2022; 44(1):171-185. PubMed ID: 36093649
[TBL] [Abstract] [Full Text] [Related]
19. Low brca1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a diagnosis of epithelial Tubo-ovarian Carcinoma.
Bernard J; Mehros W; Gregoire J; Douville P; Renaud MC; Sebastianelli A; Langlais EL; Plante M
J Obstet Gynaecol Can; 2022 Oct; 44(10):1047-1053. PubMed ID: 35779836
[TBL] [Abstract] [Full Text] [Related]
20. Predicting the likelihood of a
Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell C; Salih Z; Woodward ER; Lalloo F; Shaw J; Desai S; Crosbie EJ; Edmondson RJ; Schlecht H; Wallace AJ; Jayson GC; Evans DGR
J Clin Pathol; 2023 Oct; 76(10):684-689. PubMed ID: 35738887
[TBL] [Abstract] [Full Text] [Related]
[Next]
